| Patent application number | Description | Published |
|---|
| 20090215747 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES - This invention discloses and claims methods for inhibiting bacterial β-lactamases and treating bacterial infections by inhibiting bacterial β-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a β-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a β-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed. | 08-27-2009 |
| 20100048528 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES - This invention discloses and claims methods for inhibiting bacterial β-lactamases and treating bacterial infections by inhibiting bacterial β-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a β-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a β-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed. | 02-25-2010 |
| 20110021772 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents - The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: | 01-27-2011 |
| 20110213147 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents - The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: | 09-01-2011 |
| 20110245254 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES - This invention discloses and claims methods for inhibiting bacterial β-lactamases and treating bacterial infections by inhibiting bacterial β-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a β-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a β-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed. | 10-06-2011 |
| Patent application number | Description | Published |
|---|
| 20080262648 | DEMAND-DRIVEN SALES MODEL CAPITALIZING ON THE POWER OF ONLINE COMMUNITY - The business method according to the present invention concerns with spatially distributed configurable vending machines and their network, especially those which produce FMCG products, like beverages, hot drinks, cocktails, soups, soaps, perfumes, etc. The configurable vending machine can produce products in different phase, proportion, appearance, look and feel, etc. regarding its configuration set up. The different configurations are generally called recipe, formula which are stored in files in Internet servers. These files can be accessed by authorized persons, who can modify, delete, create new and share with other authorized users via an Internet based online community portal. The invention describes how the configurable vending machines and its network can be managed and the communication among consumers, resellers and franchise owner. The IT back office system automatically organizes product development, market survey, marketing communication, and logistics processes and serve information about actual trends, consumption, stock status in real-time. Variety of advantages are obtained by using the method invented, like a higher integration among B2C, B2B and C2C domains (processes) yielding shorter product development cycles, lower sales and development costs, and better market knowledge. | 10-23-2008 |
| Patent application number | Description | Published |
|---|
| 20080293761 | Pyrrolopyridine-2-Carboxylic Acid Amide Derivative Useful as Inhibitor of Glycogen Phosphorylase - The present invention is directed to a novel form of a pyrrolopyridine-2-carboxylic acid amide of formula (I), which is an inhibitor of glycogen phosphorylase, compositions containing it and their use in therapy. The invention is also directed to processes for production of the novel form, novel intermediates used in said processes and processes for the production of said intermediates. | 11-27-2008 |
| 20100267988 | PROCESSES FOR PREPARING INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF CINACALCET - The invention relates, in general, to an improved process for preparing compounds (e.g., 3-(3-trifluoromethylphenyl)propanal (Compound III, below)), which are key intermediates for the synthesis of cinacalcet, its salts and/or solvates thereof, as well as the use of such compounds prepared by such process for the preparation of cinacalcet and/or its salts or solvates. | 10-21-2010 |
| 20110295037 | PROCESSES FOR PREPARING CINACALCET HYDROCHLORIDE AND POLYMORPHIC FORMS THEREOF - The invention relates to cinacalcet hydrochloride, new polymorphic crystalline forms of cinacalcet hydrochloride, amorphous cinacalcet hydrochloride and synthetic processes for their preparation. | 12-01-2011 |
| Patent application number | Description | Published |
|---|
| 20110214360 | GUTTER CLAW - This invention, ‘The Gutter Claw’, enables a typical do-it-yourself home or business property owner to more easily maintain and upkeep a rooftop gutter run-off system. By adding ‘The Gutter Claw’ to all down pipes/leader pipes (drainage down pipes that typically get clogged below ground due to seasonal debris accumulation), removal of debris from within the down pipe can be done more easily and conveniently. There an many advantages to the application of this invention, including where it can be located on any given down pipe at eye level, which works well with the easy remove and replace features on the molded parts' design. | 09-08-2011 |
| 20110222985 | Wing Wall Anchor - Essentially this invention the Wing Wall Anchor is unique because the wings are opened parallel to the wall by the spring which is riveted between the by the nut/rivet connector. The spring opens the wings even when they are adjacent to a stud a corner wall. Also because of the size, length, width, gauge, they are able to hold more securely and require substantially less backspace and a 50% shorter bolt than similar anchors. | 09-15-2011 |
| 20110226798 | Vita-Spence - Essentially this invention, the Vita-Spence will aid the consumer in tracking the consumption of vitamins or pills each day for one or two week intervals. It will also eliminate the daily drudge of opening and closing of two to ten jars daily as well as the aforementioned benefits to large number vitamin and pill takers, especially among the elderly people with slightly diminished capabilities. | 09-22-2011 |
| Patent application number | Description | Published |
|---|
| 20080287553 | PHARMACEUTICAL COMPOSITIONS COMPRISING PERANHYDROCYCLODEXTRIN - The present invention relates to a pharmaceutical composition comprising a peranhydrocyclodextrin, a drug and a carrier, to the use of a peranhydrocyclodextrin as a drug transport enhancer (e.g. permeation enhancer), and to the use of a peranhydrocyclodextrin in the preparation of a pharmaceutical composition as a synergistic adjunctive system. | 11-20-2008 |
| 20080299166 | NOVEL BIOMATERIALS, THEIR PREPARATION AND USE - The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps:
| 12-04-2008 |
| 20090110734 | QUATERNISED AMMONIUM CYCLODEXTRIN COMPOUNDS - Use of a compound of formula (I): | 04-30-2009 |
| 20100056476 | PHARMACEUTICAL COMPOSITIONS COMPRISING PERANHYDROCYCLODEXTRIN - The present invention relates to a pharmaceutical composition comprising a peranhydrocyclodextrin, a drug and a carrier, to the use of a peranhydrocyclodextrin as a drug transport enhancer (e.g. permeation enhancer), and to the use of a peranhydrocyclodextrin in the preparation of a pharmaceutical composition as a synergistic adjunctive system. | 03-04-2010 |
| 20120004158 | Quaternised Ammonium Cyclodextrin Compounds - Use of a compound of formula (I): | 01-05-2012 |
| 20120040901 | NOVEL BIOMATERIALS, THEIR PREPARATION AND USE - The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps:
| 02-16-2012 |
| Patent application number | Description | Published |
|---|
| 20080200668 | Industrial Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene-3-Oxo-17Alpha-Pregn-4-Ene-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process - The invention relates to an industrial process for the preparation of 17-hydroxy-6β,7β;15β,16β-bismethylene-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone of formula (I), and to the key-intermediates for this process. | 08-21-2008 |
| 20090216009 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS - An industrially easily realizable and economical process comprising only few steps, and built on new intermediates for the production of 1-(4-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone (ezetimibe) according to the reaction scheme described herein. | 08-27-2009 |
| 20100137622 | INDUSTRIAL METHOD FOR THE SYNTHESIS OF 17-ACETOXY-11beta-[4-(DIMETHYLAMINO)-PHENYL]-21-METHOXY-19-NORPREGNA-4,9-- DIEN-3,20-DIONE AND THE KEY INTERMEDIATES OF THE PROCESS - The present invention relates to a process for the synthesis of the known 17-acetoxy-11-β-[4-(dimethyl amino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione (further on CDB-4124) of formula (I) from 3,3-[1,2-ethandiyl-bis(oxy)]-oestr-5(10),9(11)-dien-17-one of formula (II). Compound CDB-4124 belongs to the group of anti-hormones. The process has the following steps: i) formation of an epoxide; ii) addition of hydrogen cyanide; iii) silylation of a hydroxyl group; iv) reaction with 4-(dimethylamino)-phenyl magnesium bromide Grignard reagent in the presence of CuCl (Teutsch reaction); v) silylation of a hydroxyl group with trimethyl chlorosilane; vi) reaction with diisobutyl aluminum hydride and after addition of acid to the reaction mixture; vii) methoxy-methylation with methoxy-methyl Grignard reagent formed in situ, while hydrolyzing the trimethylsilyl protective groups; viii) oxidation of a hydroxyl group with dicyclohexyl carbodiimide in the presence of dimethyl sulfoxide and a strong organic acid (Swern oxidation), and in given case after purification by chromatography; ix) acetylation of a hydroxyl group with acetic anhydride in the presence of perchloric acid, and in given case, purification by chromatography. The invention also relates to new intermediates of the process. | 06-03-2010 |
| Patent application number | Description | Published |
|---|
| 20080278057 | BULB-SHAPED OUTER ENVELOPE FOR LAMPS, METHOD FOR MANUFACTURE THEREOF, AND COMPACT FLUORESCENT LAMP THEREWITH - A bulb-shaped outer envelope for accommodating at least one lamp including a light-emitting body and a control gear is disclosed. The envelope has a substantially spherical section for receiving the light-emitting body, and an elongated end section for receiving at least a part of the control gear components. The elongated end section is provided with a neck section. A substantially tubular neck-extension portion connects to an inner surface portion of and protruding from the neck section. The neck-extension portion is suitable for accommodating a remaining part of the control gear components. In a method for the manufacture of a glass outer envelope, a flare that is normally used in the manufacture of incandescent lamps is turned around by 180°, put into a skirted bulbous envelope, melted into the envelope while the skirt is detached and the flare is formed into a neck-extension portion. A self-ballasted compact fluorescent lamp with the bulb-shaped outer envelope is also disclosed. A part of the ballast components are disposed in the neck-extension portion of the outer envelope. | 11-13-2008 |
| 20090167184 | COMPACT FLUORESCENT LAMP WITH MECHANICAL SUPPORT MEANS AND STARTING AID - The compact fluorescent lamp comprises a bulb shaped outer envelope enclosing a discharge tube having a coiled configuration and a ballast unit for controlling the current in the tube. The lamp further comprises at least one joint mechanical support and starting aid means for positioning the discharge tube and the ballast unit and reducing a breakdown voltage path of the discharge tube. The at least one mechanical support and starting aid means is made of an electrically conducting material and connected electrically to at least one of the electrodes. The neck portion has a retaining member, and the mechanical support and starting aid means is supported by the retaining member and clamped on the discharge tube at least at a location in a vicinity of a middle section of the arc path. The mechanical support means further comprises at least one support section to provide support against an apex of the outer envelope, and at least one fixing section for fixing of the discharge tube. | 07-02-2009 |
| 20100026162 | FIXING MECHANISM FOR AN INNER ASSEMBLY TO OUTER BULB - A lamp assembly includes an inner assembly that has a CFL source, an electronics board, and a holder that interconnects the CFL source and electronics board. An outer, light transmissive envelope surrounds the inner assembly and various fixing arrangements are disclosed for securing the inner assembly to the outer envelope. Three primary mechanisms are a ratchet mechanism, a spring mechanism, or using adhesive to secure the inner assembly to the outer envelope under a predetermined tension. | 02-04-2010 |
| 20100026182 | ELECTRIC LAMP WITH INNER ASSEMBLY AND OUTER BULB AND METHOD FOR MANUFACTURING - An electric lamp comprises an inner assembly including a light source and a control gear circuit. An outer envelope encloses the light source and at least a part of the control gear and has a predetermined wall thickness and an end portion. The outer envelope is comprised of two parts separated along a circumferential line. The two parts of the envelope are connectable and sealable to form a uniform outer envelope with a seal region. The seal region has a wall thickness and is merged in a surface portion of the two parts of the envelope so that the surface unevenness of the seal region is not greater than 0.5 millimeters, and the maximum difference of the wall thickness of the seal region with respect to the wall thickness of the outer envelope is not greater than 0.3 millimeters. | 02-04-2010 |
| 20100181911 | HOLDER FOR INTEGRAL COMPACT FLUORESCENT LAMP WITH OUTER BULB - A lamp assembly having a CFL light source includes an outer envelope received around the light source. The outer envelope includes a first enlarged portion dimensioned for receipt about the light source and a second narrowed portion adapted for connection with a lamp base. A platform receives a first end of the CFL light source and supports the CFL within the envelope, the platform including a tapered perimeter portion dimensioned for abutting engagement with an interior surface of the envelope. | 07-22-2010 |
| 20110012509 | COMPACT FLUORESCENT LAMP AND METHOD FOR MANUFACTURING - This compact fluorescent lamp comprises a discharge tube arrangement with at least one discharge tube. The tube is formed of glass, encloses a discharge volume filled with a discharge gas and has a fluorescent phosphor coating disposed on the inner surface of the tube. The tube forms a continuous arc path and the tube is provided with electrodes disposed at each end of the arc path. The lamp also comprises a ballast circuit connected to the electrodes for controlling the current in the tube and a lamp base for connecting said lamp to a power supply through a socket. The lamp is enclosed in an outer envelope comprising a substantially spherical portion enclosing the tube arrangement and an elongated end portion enclosing the ballast circuit. The end portion of the outer envelope is closed and sealed by a sealing means of the same material as the material of the outer envelope. The sealing means is connected to the envelope in a hermetically sealing way. | 01-20-2011 |
| 20110234094 | FAST WARM-UP AND INSTANT LIGHT ENERGY SAVING LAMP ASSEMBLY - A lamp assembly provides both instant light through use of an incandescent/halogen lamp source and an energy saving type light provided by a compact fluorescent lamp source. Both light sources are enclosed within a common envelope or outer bulb. The sensor member monitors a temperature of the cathode and mercury reservoir of the compact fluorescent lamp source in order to determine when to terminate power to the incandescent lamp source. | 09-29-2011 |
| 20110298356 | POSITIONING OF AUXILIARY AMALGAM - A compact fluorescent lamp includes a discharge tube having cathodes disposed adjacent opposite ends. A fill gas which includes mercury is disposed within the discharge tube. The lamp further includes an amalgam located in the discharge tube and dispersed in the arc to be heated thereby for emitting mercury vapor during at least a starting period. | 12-08-2011 |
| 20120007486 | LED LIGHT SOURCE IN INCANDESCENT SHAPED LIGHT BULB - An LED light bulb that includes a base providing an electrical connector and a substantially hollow envelope extending from the base. The light bulb further includes a metal space separator having a top side, bottom side and side wall that has a plurality of holes connected by at least one channel that extends through the interior of the separator, such that air can pass through the separator. At least one LED is mounted on the separator in electrical connection with the base connector. | 01-12-2012 |
| 20120019136 | COMPACT FLUORESCENT LAMP WITH IMPROVED THERMAL MANAGEMENT - A compact fluorescent lamp includes an inverted compact fluorescent light source housed within an outer envelope. Locating the first and second ends of the coiled CFL source positions the electrodes within a substantially spherical outer envelope at a location remotely spaced from the ballast compartment. In this manner, only small diameter first and second lead wires that mechanically and electrically engage the electrodes pass through small dimensioned passages in a separation member in the outer envelope cavity. This substantially reduces the thermal stress on the components. | 01-26-2012 |
| 20120104948 | COMPACT FLUORESCENT LAMP WITH IMPROVED PERFORMANCE AND SIZE - A compact fluorescent lamp includes a discharge tube forming a continuous arc path with electrodes disposed at each end of the path. The lamp includes a fill gas disposed within the discharge tube. The lamp further includes a ballast circuit for controlling current in the discharge tube and operatively connected to the electrodes. The discharge tube is spirally wound around the longitudinal axis of the lamp to form a partially closed cavity and in a preferred arrangement the ballast is positioned within cavity formed by the spirally wound discharge tube. A gap between adjacent turns of the spirally wound discharge tube is less than about 0.5 mm, and preferably about 0.0009 mm. | 05-03-2012 |
| Patent application number | Description | Published |
|---|
| 20090253743 | COMPOSITIONS OF TOLPERISONE - The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features. | 10-08-2009 |
| 20090326219 | PROCESS FOR MANUFACTURING EXTREMELY PURE BENZAZEPINE DERIVATIVES - A process for the production of extremely pure galanthamine or extremely pure galanthamine derivatives, a start is made from racemic bromine narwedine, which is debrominated under palladium catalysis. In this case, the working-up of the reaction mixture, which is carried out in the presence of oxygen or peroxides so that the palladium catalyst in an insoluble form is converted into an easily separable form, is essential. The further reaction is carried out by reduction of enantiomer-pure narwedine to form enantiomer-pure galanthamine, whereby it is then alkylated or dealkylated so that a corresponding substitution on the ring-nitrogen atom is achieved. By further purification, such as recrystallization, residual portions of palladium of below 5 ppm are achieved, so that direct use as a pharmaceutical raw material is made possible. | 12-31-2009 |
| 20100150995 | PROCESS FOR THE PRODUCTION OF HIGH-PURITY 2,4'-DIMETHYL-3-PIPERIDINO-PROPIOPHENONE (TOLPERISONE), PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THE LATTER, AS WELL AS ACTIVE INGREDIENT FORMULATIONS THAT CONTAIN TOLPERISONE - The invention relates to a method for producing highly pure 2,4′-dimethyl-3-piperidino-propiophenone (tolperisone) (formula I) and the pharmaceutically acceptable salts, hydrochlorides, and hydrates thereof. The method allows the content of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) to be kept significantly lower than in previously known methods. The invention further relates to active substance formulations which contain tolperisone and are suitable, among other things, for producing combination preparations used for treating patients suffering from Alzheimer's disease. The invention also relates to topical formulations, controlled release (CR) formulations, and transdermal therapeutic systems, such as active substance patches, which contain less than 50 ppm, preferably less than 10 ppm, more preferably less than 7 ppm, and most preferably less than 3 ppm or 0 ppm (i.e. less than the detectable amount) of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) in relation to 100 percent by weight of active substance. | 06-17-2010 |
| 20100249423 | TOLPERISONE CONTROLLED RELEASE TABLET - A GRDDS (Gastro Retentive Drug Delivery System) containing tolperisone and having a 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) fraction of less than 1.5 ppm for the extended release of the active substance tolperisone while avoiding the formation of 4-MMPPO in the gastrointestinal tract. | 09-30-2010 |
| 20100324090 | COMPOSITIONS OF TOLPERISONE - The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features. | 12-23-2010 |
| Patent application number | Description | Published |
|---|
| 20100068745 | PROCESS AND KIT FOR MEASURING THE CONDITION OF THE FIBRINOLITIC SYSTEM - The invention relates to an assay and a kit for the determination of the status of the fibrinolytic system. In particular the invention relates to a method for the determination of the status of the fibrinolytic system from tear fluid samples. Additionally the invention relates to a sterilized, calibrated capillary equipped with a plastic balloon, suitable for tear fluid sampling, and a kit for the assessment of the status of the fibrinolytic system, or for the determination of its balance, comprising a sampling capillary, reaction sheets, color scale to help the evaluation, and reagents | 03-18-2010 |
| 20110028397 | Use of Urokinase Type Plasminogen Activator Inhibitors for the Treatment of Corneal Disorders - The invention concerns the use of inhibitors of the urokinase type of plasminogen activator (uPA) appearing in the anterior segment of the eye, for the treatment and prevention of corneal ulcers and other disorders. The invention further concerns pharmaceutical compositions, comprising inhibitors of uPA, preferably eye drops and eye ointments. The pharmaceutical compositions according to the invention preferably comprise PAI-2 protein or a derivative thereof retaining uPA-inhibiting capacity, or a tripeptide aldehyde inhibitor, preferably the D-Phe-Pro-Arg-aldehyde (Ald-1). The PAI-2 protein, used according to the invention, is preferably produced through bacterial expression, as a fusion protein. | 02-03-2011 |
